MediSieve raises seven-figure funding led by 24Haymarket to advance blood filtration technology.
The round was led by 24Haymarket with a £632k contribution to support product development.
Share allotment filed at Companies House
MediSieve has developed a magnetic blood filtration platform designed to remove harmful components directly from the bloodstream. The firm focuses on targeted treatments for serious blood-borne conditions.
MediSieve has secured seven-figure funding in a round led by 24Haymarket, which contributed £632k. As part of the transaction, Marek Gumienny from the investor has joined the company board as a non-executive director.
The capital will support ongoing research and product development for the company's magnetic blood filtration device, which aims to treat conditions such as malaria, sepsis and leukaemia by filtering targeted components from the bloodstream.
Founder and chief executive George Frodsham noted that the financing provides essential resources for commercialisation. The company intends to use the backing to scale its operations over the coming years.
From the founder
"This investment represents a watershed moment for MediSieve, and gives us the resources required to move forward with our product development and commercialisation over the coming years."
George Frodsham
CEO at MediSieve
Investor perspective
"MediSieve is an excellent example of the type of businesses 24Haymarket is proud to back."
Marek Gumienny
Director, 24Haymarket
Use of funds
- 01Fund research and development
- 02Continue product development
